



BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015. Fax : 0731-2723017
Tel. : 0731-2723016, 4066216 E-mail : biofilchemicals@yahoo.com / bcplcompliance@gmail.com
Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)
Tel. : 0731-2426700, 2426718, 2524003, Fax : 0731-2426726 • CIN : L24233MP1985PLC002709

Online filing at listing.bseindia.com

30th May, 2017

To,
The Secretary,
Corporate Relationship Department,
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400 001

To,
The Company Secretary,
Corporate Compliance Department
The National Stock Exchange of India Limited
Bandra Kurla Complex, Mumbai

Sub: Submission Audited Financial Results for the Quarter as well year ended 31st March, 2017 as terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref: BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED (BSE Scrip Code: 524396; Symbol: BIOFILCHEM; ISIN: INE829A01014)

Dear Sir/Madam,

This is in continuation of our letter dated 22nd May, 2017 regarding information for Board Meeting for consideration and approval Audited Financial Results for the quarter as well as year ended 31st March, 2017.

In compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to submit the Audited Financial Results for the quarter as well as year ended 31st March, 2017 duly approved by the Board at its meeting held on Tuesday, 30th May, 2017 at the registered office of the Company together with Auditors Report thereon, Statement of assets and liabilities and declaration by the Managing Director of the Company pursuant to second proviso of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The meeting of the Board of the directors was commenced at 4.00 P.M. and concluded at 5.00 P.M.

Further above result shall also be submitted in XBRL mode (Excel Template provided by Exchange) within 24 hours from the conclusion of Board Meeting.

The aforesaid results will be published in one Hindi (vernacular) and widely circulated English Newspaper. These results shall also be uploaded on the Company's website www.biofilgroup.net and on the website of the Stock Exchange at www.bseindia.com and nseindia.com

You are requested to take the same on record.

Thanking You,
Yours faithfully
For, Biofil Chemicals and Pharmaceuticals Limited



Ramesh Shah
Managing Director
DIN :00028819
Encl: a/a



Audited Financial Results of Quarter and Year Ended of March . 2017
 31-03-2017 of M/s. Biofil Chemicals & Pharmaceuticals Limited
 11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)
 CIN L24233MP1985PLC002709
 AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st March , 2017

(Amount in Lakhs)

Statement of Standalone Financial Results for the Quarter & Year ended 31st March 2017					
Particulars	For the Quarter ended March 31 2017	For the quarter ended December 31 2016	For the Quarter ended March 31 2016	Audited for the year ended March 31 2017	Audited for the year Ended March 31 2016
	Audited	Reviewed	Audited	Audited	Audited
1 Income from operations					
(a) Net sales/ income from operations (Net of Excise duty)	198.03	396.17	287.54	918.44	1085.65
(b) Other operating income	427.62	0.55	234.59	429.30	251.65
Total income from operations (net)	625.66	396.71	522.13	1347.74	1337.30
2 Expenses					
(a) Cost of materials consumed	30.22	29.32	47.26	90.41	121.34
(b) Purchases of stock-in-trade	330.93	253.68	1.90	702.02	932.53
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	16.03	(12.52)	285.07	(1.32)	0.58
(d) Employee benefits expense	25.40	12.71	27.97	53.22	48.23
(e) Depreciation and amortisation expense	8.85	6.51	6.70	28.42	26.49
(f) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	65.23	54.05	85.45	179.08	127.42
Total expenses	476.67	343.76	454.34	1111.83	1256.58
3 Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	148.99	52.96	67.78	235.90	80.71
4 Other income	6.04	0.00	7.98	11.49	32.55
5 Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	157.03	52.96	75.76	247.40	113.26
6 Finance costs	5.11	3.75	3.97	16.36	15.19
7 Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 + 6)	151.92	49.21	71.79	231.04	98.07
8 Exceptional items	1.62		1.12	1.62	1.12
9 Profit / (Loss) from ordinary activities before tax (7 + 8)	150.30	49.21	70.67	229.42	96.95
10 Tax expense	50.00		18.69	50.00	18.69
11 Net Profit / (Loss) from ordinary activities after tax (9 ± 10)	100.30	49.21	51.98	179.42	78.26
12 Extraordinary items (net of tax Rs expense lakhs)	100.30	49.21	51.98	179.42	78.26
13 Net profit/(loss) for the period (11±12)					
14 Share of Profit/Loss of Associates					
15 Minority Interest					
16 Net Profit/(loss) after taxes, minority interest and share of profit/(Loss) of associates after tax (13±14±15)	100.30	49.21	51.98	179.42	78.26
17 Paid up Equity Share Capital (Face value of the share shall be indicated)	1627.38	1627.38	1627.38	1627.38	1627.38
18 Reserve excluding Revaluation Reserve as per the Balance Sheet of previous accounting year				-733.93	-913.35
19.i Earnings per share (before extraordinary items)					
(of Rs. 10/- each) (not annualised):					
(a) Basic		0.62	0.302	0.32	1.10
(b) Diluted		0.62	0.302	0.32	1.10
19.ii Earnings per share (after extraordinary items)					
(of Rs. 10/- each) (not annualised):					
(a) Basic		0.62	0.302	0.32	1.10
(b) Diluted		0.62	0.302	0.32	1.10



The above audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 30th Day of May, 2017

The figures of last quarter are the balancing figures between audited figures in respect of the full financial year and published year to date figure up to third quarter of the current financial year

Previous year period's/year's figures have been regrouped wherever necessary to conform to the current period's classification.

The Company has reported segment wise information as per Accounting Standard (AS-17). The Operations of the company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments


1. Pharma Product
2. Chemicals Division
3. Plastic Division

The aforesaid audited financial Results will be uploaded on the Company's website www.biofilgroup.net and will also be available on the websites of the Stock exchanges i.e. www.bseindia.com and www.nseindia.com for the benefit of shareholders and investors

Date 30/05/2017
Place Indore

FOR Biofil Chemicals & Pharmaceuticals Limited

RAMESH SHAH
MANAGING DIRECTOR
(DIN : 00028819)




BIOFIL CHEMICALS & PHARMACEUTICALS Ltd.
AUDITED STATEMENT OF ASSETS AND LIABILITIES AS AT 31-03-2017
CIN NO. L24233MP1985PLC002709

(In Rs.)

Standalone / Consolidated Statement of Assets and Liabilities Particulars		standalone	
		31, March 2017 Audited	31, March 2016 Audited
A	EQUITY & LIABILITIES		
1	Shareholders' funds		
	(a) Share Capital	162738000	162738000
	(b) Reserves & Surplus	-35772529	-53670404
	(c) Money received against share warrants		
	Sub-total - Shareholders' funds	126965471	109067597
2	Share application money pending allotment		
3	Minority interest *		
4	Non-current liabilities		
	(a) Long-term borrowings		
	(b) Deferred tax liabilities (net)		
	(c) Other long-term liabilities		
	(d) Long-term provisions		
	Sub-total Non-current liabilities		
5	Current liabilities		
	(a) Short-term borrowings	14280916	13699750
	(b) Trade payables	70952226	115918453
	(c) Other current liabilities	-	-
	(d) Short-term provisions	6205269	2633609
	Sub-total Current liabilities	91438411	132251812
	TOTAL - EQUITY AND LIABILITIES	218403882	241319409
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets		
	Tangible Assets	91645276	89755340
	(b) Goodwill on consolidation *		
	(c) Non-current investments		
	(d) Deferred tax assets (net)		
	(e) Long-term loans and advances		
	(f) Other non-current assets		
	Sub-total - Non-current assets	91645276	89755340
2	Current assets		
	Current investments		
	Inventories	1662981	960220
	Trade receivables	114644117	139846275
	Cash and cash equivalents	3096726	1808146
	Short-term loans and advances	4479860	5209803
	Other current assets	2874921	3739625
	Sub-total - Current assets	126758605	151564069
	TOTAL - ASSETS	218403882	241319409

DATE : 30/05/2017
 PLACE : INDORE


BIOFIL CHEMICALS & PHARMACEUTICALS LTD.
RAMESH SHAH
MANAGING DIRECTOR
DIN: 00028819




BIOFIL CHEMICALS & PHARMACEUTICALS LTD.
CIN NO. L24233MP1985PLC002709


Segmentwise Revenue, Results an Capital Employed for year ended 31st March 2017

(Amount in Lakhs)

S.No.	Segment Revenue	Quarter Ended			Year Ended	
		March 31 ,	December 3	March 31 ,	31 March	31 March
		2017	2016	2016	2017	2016
		Audited	Reviewed	Audited	Audited	Audited
1	Segment Revenue	662.49	357.07	479.52	1205.08	1160.00
	Pharma Unit	41.23	38.10	33.01	139.08	134.52
	Chemicals Division	0.28	1.00	6.51	1.28	22.62
	Plastic Division	(70.30)	0.55	11.06	13.79	52.70
	Other	633.70	396.71	530.11	1359.23	1369.85
	Gross Turnover					
2	Segment Results	156.00	56.70	139.00	252.24	148.07
	Pharma Unit	(29.57)	0.31	(63.77)	(21.46)	(32.02)
	Chemicals Division	6.72	(4.05)	(4.10)	(7.26)	(7.39)
	Plastic Division	19.84	0.00	2.29	19.84	2.29
	Other					
	Total Segment Profit Before Tax	152.99	52.96	73.42	243.36	110.95
	Interest Income	2.69	0.00	2.18	2.69	2.18
	Interest Expenses	3.76	3.75	3.81	15.01	15.06
	Other Unallocable Income net of Expenditure					
	Profit Before Tax	151.92	49.21	71.79	231.04	98.07
	Provision for current tax	50.00	0.00	18.69	50.00	18.69
	Item Related Earlier Year	1.62		1.12	1.62	1.12
	Profit After Tax	100.30	49.21	51.98	179.42	78.26
3	Capital Employed					
	Segment Assots (A)					
	Pharma Division	1309.64	1242.61	1554.61	1309.64	1554.61
	Chemicals Division	802.50	772.24	761.22	802.50	761.22
	Plastic Division	71.90	78.34	97.37	71.90	97.37
	Other		0.00			
	Total (A)	2184.04	2093.19	2413.19	2184.04	2413.19
	Segment Liabilities (B)					
	Pharma Division	703.01	736.48	1158.44	703.01	1158.44
	Chemicals Division	66.53	20.90	38.99	66.53	38.99
	Plastic Division	144.85	148.59	143.78	144.85	143.78
	Other					
	Total (B)	914.38	905.96	1341.21	914.38	1341.21
	Total Capital Employed	1269.65	1187.23	1071.99	1269.65	1071.99

DATE : 30-05-2017
 PLACE : INDORE

BIOFIL CHEMICALS & PHARMACEUTICALS LTD.
 INDORE

 RAMESH SHAH
 MANAGING DIRECTOR
 DIN: 00028819





BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

Regd. Office : 11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015. Fax : 0731-2723017
Tel. : 0731-2723016, 4066216 E-mail : biofilchemicals@yahoo.com / bcplcompliance@gmail.com
Factory : Plot No. 8, Sector - IV, Kheda Industrial Area, Pithampur Distt. Dhar (M.P.)

Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)
Tel. : 0731-2426700, 2426718, 2524003, Fax : 0731-2426726 • CIN : L24233MP1985PLC002709

30th May, 2017

Online filing at listing.bseindia.com

To,
The Secretary,
Corporate Relationship Department,
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400 001

To,
The Company Secretary,
Corporate Compliance Department
The National Stock Exchange of India Limited
Bandra Kurla Complex, Mumbai

Sub: Submission of declaration regarding unmodified opinion of the Auditors on Annual Audited Financial Results of the Company for the year ended 31st March, 2017 as per second proviso to Regulation 33(3)(d) of SEBI (LODR) Regulations, 2015

Ref: BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED (BSE Scrip Code: 524396; Symbol: BIOFILCHEM; ISIN: INE829A01014)

Dear Sir/Madam,

DECLARATION

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 I, the undersigned do hereby declare that in the Audit Report accompanying Annual Audited Financial Statements of Biofil Chemicals and Pharmaceuticals Limited for the financial year ended on 31st March, 2017, the Auditor did not express any modified opinion/audit qualification or other reservation and accordingly, the Statement on Impact of Audit Qualifications is not required to be given.

You are requested to please consider and take on record the same.

Thanking You,
Yours faithfully
For, Biofil Chemicals and Pharmaceuticals Limited

Ramesh Shah
Managing Director
DIN :00028819
Encl: a/a





S.N. Gadiya & Co.
(Chartered Accountants)

Satya Narayan Gadiya
F.C.A., B. Com.
Mob. : 9301503126

Auditor's Report On Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors
Biofil Chemicals and Pharmaceuticals Limited
Indore (M.P.)

We have audited the quarterly financial results of Biofil Chemicals and Pharmaceuticals Limited for the quarter ended on 31st March, 2017 and the year to date results for the period 1st April, 2016 to 31st March, 2017, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the financial statements, which are the responsibility of the company's management.

Our responsibility is to express an opinion on these financial results based on our audit of such financial statements, which have been prepared in accordance with Accounting Standard notified under Section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- (ii) give a true and fair view of the net profit and other financial information for the quarter ended on 31st March 2017 as well as the year to date results for the period from 1st April 2016 to 31st March 2017.

Place: Indore
Date: 30.05.2017



For S.N. Gadiya & Co
Chartered Accountant
FRN: 002052C

(S.N. Gadiya)
Proprietor
M No. 071229